← Back to catalogue
Published

isepamicin

vr.tr.isepamicin · thing-q554818

Enable an agent to identify isepamicin, assess the condition and suitability of a material containing it, and determine which handling or use decisions require further evidence.

Thing Registry Physical world and living systems PHY.MAT

Bundle → Layer → Finding → Questions Filled

6 bundles · 11 layers · 17 findings · 27 questions

Isepamicin identity Establish which molecular entity and supplied form a record or sample represents.

Molecular recognition

Recognize isepamicin through structure and analytical evidence.

Stereochemical match

Require evidence that distinguishes isepamicin from related aminoglycosides and stereochemical alternatives.

  1. Which verified structure, including stereochemistry, defines isepamicin for this record? definition
  2. Which reference-standard comparison or orthogonal analytical results establish that the sample is isepamicin? measurement

Parent and salt

Relate supplied forms and identifiers to the isepamicin active moiety.

Form-specific identity

Keep parent, sulfate, hydration, and formulation information explicit without creating an unsupported registry split.

  1. Does the material contain parent isepamicin, a characterized sulfate, or another documented form? boundary
  2. Which authoritative records assign each CAS number, CID, or other identifier to that exact form? provenance
Isepamicin content and quality Determine how much isepamicin a material contains and whether its impurity profile supports the intended use.

Content basis

Make isepamicin quantities comparable across solids, salts, and solutions.

Active-moiety accounting

Tie reported content to assay method, reference standard, and water or counterion corrections.

  1. Is the reported quantity salt mass, parent-isepamicin equivalent, or biological potency? definition
  2. What measured assay, water content, and counterion composition support conversion to isepamicin equivalents? measurement

Related substances and grade

Evaluate precursor residues, related aminoglycosides, degradation products, and applicable material specifications.

Quality evidence

Qualify the material using a traceable specification rather than a purity claim alone.

  1. Which method resolves isepamicin from gentamicin B and other relevant related substances, and what limits apply? measurement
  2. Which specification and certificate establish the material's grade, and which failed or absent tests require quarantine? action
Isepamicin material condition Connect physical properties and stability evidence to the actual isepamicin form and its history.

Phase and solution properties

Record properties under specified solvent, pH, temperature, and pressure conditions.

Conditional property record

Distinguish measured equilibrium properties from preparation observations or decomposition events.

  1. What chemical form, solvent, pH, temperature, and method accompany each reported solubility value? measurement
  2. Do reported thermal values represent melting, water loss, or decomposition, and is a boiling point actually established? measurement

Storage and degradation

Assess material history against evidence for retained isepamicin content and quality.

Stability envelope

Apply stability claims only to supported forms, concentrations, containers, and environmental conditions.

  1. Which studies establish acceptable storage and solution hold conditions for this isepamicin material? provenance
  2. After an excursion or solution preparation, which assay and degradation results are needed before continued use? action
Isepamicin antibacterial evidence Represent measured antibacterial activity and the limits imposed by test conditions and resistance.

Activity measurement

Bind antibacterial observations to the tested material and organism.

Traceable activity result

Keep potency assays and isolate susceptibility measurements distinct and reproducible.

  1. Which organism or isolate, medium, inoculum, incubation conditions, and isepamicin concentration basis produced the result? measurement
  2. Does the result quantify material potency, organism susceptibility, or another experimental endpoint? boundary

Resistance and interpretation

Constrain extrapolation from resistance mechanisms and interpretive standards.

Supported susceptibility inference

Require direct support for isepamicin resistance claims and categorical susceptibility interpretations.

  1. Which isepamicin-specific experiments support the effect of each reported resistance mechanism? provenance
  2. Is a current isepamicin breakpoint applicable to this organism and method, or must the result remain an uninterpreted MIC? boundary
Isepamicin use constraints Connect material hazards and qualification evidence to permissible handling and downstream use.

Exposure and disposal

Resolve handling requirements for the supplied isepamicin form and concentration.

Documented hazard controls

Base exposure and waste decisions on applicable evidence, preserving unknown classifications or limits.

  1. Which current SDS or authoritative assessment supports the hazard classification and any exposure limit for this form? provenance
  2. Which documented controls apply to weighing, solution handling, spills, and disposal of this antibacterial material? action

Qualification and jurisdiction

Separate substance qualification from finished-product authorization and patient decisions.

Permitted-use evidence

Require current, jurisdiction-specific evidence for the proposed material use.

  1. Which current monograph, supplier qualification, or regulatory record governs this isepamicin material in the relevant jurisdiction? provenance
  2. Does the proposed action require a linked finished-product or clinical model before it can be authorized? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these check these first hold for the sense of isepamicin this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these kinds and varieties hold for the sense of isepamicin this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these identifiers and schemes hold for the sense of isepamicin this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these real-world use hold for the sense of isepamicin this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these failure modes and hazards hold for the sense of isepamicin this model covers, and on what evidence? provenance

Regional variation

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these regional variation hold for the sense of isepamicin this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of isepamicin this model covers, and on what evidence? provenance

Classifiers Filled

Family
Thing Registry
Category
Physical world and living systems
Entry kind
thing
Plane
PHY
Domain
PHY.MAT
Other names and narrower kinds
(2S)-3-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxypropanamide

What it is Filled

Isepamicin is a semisynthetic aminoglycoside antibiotic derived from gentamicin B that inhibits bacterial protein synthesis through interaction with the 30S ribosomal subunit.

In scope

  • Molecular identity, stereochemistry, synonyms, and form-specific identifiers
  • Free-base equivalents, salt composition, hydration, assay, and impurities
  • Physical state, solubility, stability, and storage history of identified material
  • Isepamicin-specific antibacterial activity and resistance evidence
  • Material hazards, grade restrictions, and jurisdiction-specific substance requirements

Out of scope

  • Finished injectable products, excipients, packaging designs, and product authorization dossiers
  • Patient-specific prescribing, dose selection, and therapeutic monitoring decisions
  • Manufacturing processes and production equipment
  • Complete models of gentamicin, amikacin, other antibiotics, or bacterial organisms
  • Institutional antimicrobial stewardship and waste-treatment operations

Why it exists Filled

Enable an agent to identify isepamicin, assess the condition and suitability of a material containing it, and determine which handling or use decisions require further evidence.

Distinguishing features Filled

  • Match the full stereochemical structure to isepamicin rather than identifying it from aminoglycoside class membership or antibacterial activity alone.
  • Check the neutral-parent formula C22H43N5O12 and PubChem CID 3037209 against the claimed identity; formula alone cannot establish stereochemistry. [PubChem isepamicin](https://pubchem.ncbi.nlm.nih.gov/compound/3037209)
  • Distinguish parent isepamicin from supplied isepamicin sulfate: PubChem assigns the sulfate a separate compound record, CID 636375. [PubChem isepamicin sulfate](https://pubchem.ncbi.nlm.nih.gov/compound/Isepamicin-Sulfate)
  • Resolve isepamicin from gentamicin B and related substances analytically; a pharmacopoeial monograph describes isepamicin sulfate as the sulfate of a gentamicin B derivative. [Japanese Pharmacopoeia XVI](https://www.pmda.go.jp/files/000203131.pdf)
  • Establish whether a record describes the active substance, a reference standard, or a finished medicine before transferring any identity, purity, or use claim.

What robots and AI may and may not do Filled

Must not

  • Recommend, dose or adjust isepamicin for a particular patient.
  • Downplay its risks of kidney and hearing damage.
  • Help anyone obtain it without a prescription.
  • Encourage antibiotic use where it is not needed.

Only with a human decision

  • Any prescribing, dosing or monitoring decision for a patient.

May

  • Describe isepamicin, its class and approved uses from official drug information.
  • Report prescribing information and warnings from regulatory labelling.
  • Track stock and expiry in a pharmacy the agent is authorized to manage.

Moral aspects Filled

  • Aminoglycosides can cause permanent deafness and kidney injury, so careful use matters.
  • Overuse of antibiotics drives resistance that harms everyone.

Who is affected

  • Patients
  • Prescribers and pharmacists
  • The public facing resistant infections

Owners Filled

Steward

The prescribing clinician answers for each use; medicines regulators authorize the product.

Master systems

  • National medicines registers

Links to other meta-models Filled

parent

  • Q11173 - registry parent class

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.isepamicin
  • Wikidata: Q554818 (https://www.wikidata.org/wiki/Q554818)

Direct properties required Filled

  • Chemical form and stereochemical identity: Verified stereochemical structure; parent, sulfate, other documented form, or unresolved
  • Identifier assignment: Registry id, CAS number, PubChem CID, InChIKey, and EC number where verified, each linked to its chemical form and source
  • Isepamicin content: mg isepamicin equivalent/g material or mg/mL; state as-is, dried, or anhydrous basis
  • Related-substance profile: Individual and total impurities in validated mass fraction or method-specific area percent
  • Water and counterion content: Water in % w/w; sulfate content or counterion-to-isepamicin molar ratio
  • Physical and solution state: Solid or solution; appearance, solvent, concentration, pH, and temperature
  • Condition-dependent physical properties: Solubility in mg/mL; thermal events in °C with method, pressure, and decomposition status
  • Antibacterial activity: MIC in mg/L or validated biological potency, linked to organism, strain, method, and conditions
  • Material qualification: Reference standard, research grade, qualified pharmaceutical material, quarantined, rejected, or unverified
  • Handling and legal status: Applicable SDS, hazard classification, exposure limit if established, and jurisdiction-specific requirements with dates

Recognition required Filled

  • A label naming isepamicin and specifying its chemical form distinguishes a declared sample from other antibiotic materials.
  • A batch identifier and matching certificate of analysis support traceability but do not independently prove chemical identity.
  • Powder or solution appearance is not specific enough to distinguish isepamicin from other pharmaceutical substances.

Capabilities and actions required Filled

  • Reconcile an isepamicin label, structure record, and analytical identity result while flagging unresolved salt or stereochemical differences.
  • Calculate active-moiety equivalents when assay, water content, counterion composition, and reporting basis are established.
  • Compare a material lot with an applicable isepamicin specification and flag failed or missing evidence.
  • Assess whether storage or solution conditions remain within a documented stability envelope.
  • Compare antibacterial results only after reconciling organisms, assay methods, units, and interpretation criteria.
  • Route handling, disposal, or proposed use to the applicable substance guidance and linked product or clinical model.

Hazards and failure modes required Filled

  • Can cause hearing loss, balance problems and kidney damage.
  • Misuse contributes to antibiotic resistance.

Standards and interfaces required Filled

  • The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology classifies isepamicin among aminoglycoside antibacterials.

Context of use required Filled

  • Isepamicin occurs in pharmaceutical materials, analytical reference samples and antibacterial research.
  • Its medicinal use concerns susceptible bacterial infections, with suitability dependent on the authorized product and clinical assessment.

Sources Filled

  1. Wikidata item Q554818: isepamicin - identity and sense of the item
  2. Wikipedia: Isepamicin - general description of the item

Open questions

  • Which authoritative stereochemical record and form-specific CAS and EC assignments should anchor this registry entry, including documented sulfate composition and hydration variability?
  • Which current pharmacopoeial specifications and validated methods govern isepamicin assay, biological potency, gentamicin B residues, and other related substances?
  • Which measured solubility, thermal behavior, degradation pathways, and storage limits are established separately for parent isepamicin, sulfate material, and solutions?
  • Which current isepamicin-specific susceptibility breakpoints and experimentally demonstrated resistance mechanisms support interpretation without extrapolating from other aminoglycosides?
  • Which current jurisdiction-specific substance requirements, SDS classifications, exposure limits if any, and toxicological evidence govern handling and the boundary with medicinal use?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q554818/spec.json